The U.S. radiofrequency ablation devices for pain management market size was estimated at USD 477.7 million in 2025 and is projected to reach USD 1.02 billion by 2033, growing at a CAGR of 10.1% from 2026 to 2033. This growth is driven by the rising prevalence of chronic pain conditions such as arthritis and neuropathic disorders, increasing demand for minimally invasive and non-opioid treatment options, and the ongoing shift away from long-term opioid use.
Additionally, advancements in RFA technology, improved clinical outcomes, and growing awareness among both patients and healthcare providers are further supporting market expansion across the U.S.
The rising prevalence of chronic pain conditions in the U.S. is a fundamental driver for the growth of the radiofrequency ablation (RFA) devices for pain management market. Chronic pain, typically defined as pain lasting more than three months, has become one of the most common reasons for healthcare utilization. According to the Centers for Disease Control and Prevention, nearly 24.3% of U.S. adults, approximately 60 million people, experienced chronic pain in 2023, with 8.5% suffering from high-impact chronic pain that significantly limits daily activities. This expanding patient pool directly increases the demand for advanced, minimally invasive pain management solutions such as RFA, which offer targeted and longer-lasting relief compared to conventional therapies.
A key aspect contributing to market growth is the consistent upward trend in chronic pain prevalence over recent years which is linked to aging populations, sedentary lifestyles, obesity, and higher incidence of musculoskeletal and neuropathic disorders. As more patients progress from acute to chronic pain stages, the clinical need shifts toward interventional procedures like RFA, which can disrupt pain signals at the nerve level and reduce long-term dependency on pharmacological treatments. Moreover, chronic pain is strongly associated with functional limitations and reduced quality of life, making effective management a clinical priority. High-impact chronic pain affects over 21 million Americans, often impairing work productivity and daily functioning. This has encouraged healthcare providers to adopt procedures that provide sustained relief with fewer systemic side effects. RFA devices meet this demand by offering precise nerve ablation, particularly in conditions such as osteoarthritis, spinal pain, and cancer-related pain, thereby accelerating their adoption across hospitals and outpatient settings.
This product will be delivered within 1-3 business days.
Additionally, advancements in RFA technology, improved clinical outcomes, and growing awareness among both patients and healthcare providers are further supporting market expansion across the U.S.
The rising prevalence of chronic pain conditions in the U.S. is a fundamental driver for the growth of the radiofrequency ablation (RFA) devices for pain management market. Chronic pain, typically defined as pain lasting more than three months, has become one of the most common reasons for healthcare utilization. According to the Centers for Disease Control and Prevention, nearly 24.3% of U.S. adults, approximately 60 million people, experienced chronic pain in 2023, with 8.5% suffering from high-impact chronic pain that significantly limits daily activities. This expanding patient pool directly increases the demand for advanced, minimally invasive pain management solutions such as RFA, which offer targeted and longer-lasting relief compared to conventional therapies.
A key aspect contributing to market growth is the consistent upward trend in chronic pain prevalence over recent years which is linked to aging populations, sedentary lifestyles, obesity, and higher incidence of musculoskeletal and neuropathic disorders. As more patients progress from acute to chronic pain stages, the clinical need shifts toward interventional procedures like RFA, which can disrupt pain signals at the nerve level and reduce long-term dependency on pharmacological treatments. Moreover, chronic pain is strongly associated with functional limitations and reduced quality of life, making effective management a clinical priority. High-impact chronic pain affects over 21 million Americans, often impairing work productivity and daily functioning. This has encouraged healthcare providers to adopt procedures that provide sustained relief with fewer systemic side effects. RFA devices meet this demand by offering precise nerve ablation, particularly in conditions such as osteoarthritis, spinal pain, and cancer-related pain, thereby accelerating their adoption across hospitals and outpatient settings.
U.S. Radiofrequency Ablation Devices For Pain Management Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. radiofrequency ablation devices for pain management market report based on product and end-use:Product Outlook (Revenue, USD Million, 2021-2033)
- RFA Electrodes/ Probes
- Disposable
- Reusable
- RFA Cannula (or Needles)
- RFA Generators
- Others
End-use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Outpatient Facilities
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. U.S. Radiofrequency Ablation Devices for Pain Management Market: Methodology and Scope
Chapter 2. U.S. Radiofrequency Ablation Devices for Pain Management: Executive Summary
Chapter 3. U.S. Radiofrequency Ablation Devices for Pain Management: Variables, Trends, & Scope
Chapter 4. U.S. Radiofrequency Ablation Devices for Pain Management: Product Estimates & Trend Analysis
Chapter 5. U.S. Radiofrequency Ablation Devices for Pain Management: End Use Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Stryker Corporation
- Abbott Laboratories
- Medtronic plc
- Boston Scientific Corporation
- Avanos Medical, Inc
- Epimed International, Inc.
- Medline Inc.
- Elevaris Medical Devices
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 80 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 477.7 Million |
| Forecasted Market Value ( USD | $ 1020 Million |
| Compound Annual Growth Rate | 10.1% |
| Regions Covered | United States |
| No. of Companies Mentioned | 8 |
